Skip navigation
Skip navigation

Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study

Hartnett, P; Buck, M; Beale, Phillip; Goldrick, A; Allan, S; Fitzharris, B; de Souza, P; Links, M; Kalimi, G; Davies, T; Stuart-Harris, Robin


Gemcitabine and oxaliplatin have shown single-agent activity in relapsed ovarian cancer. This combination was used to determine response rates, time-to-event efficacy measures, and toxicity in patients with recurrent ovarian cancer. Patients with prior platinum-based chemotherapy who had measurable lesions and/or elevated CA-125 levels were identified as group A (platinum-refractory/platinum-resistant patients) and group B (platinum-sensitive patients). All patients received gemcitabine 1000...[Show more]

CollectionsANU Research Publications
Date published: 2007
Type: Journal article
Source: International Journal of Gynecological Cancer
DOI: 10.1111/j.1525-1438.2007.00763.x


File Description SizeFormat Image
01_Hartnett_Phase_II_study_of_gemcitabine_2007.pdf136.41 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  23 August 2018/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator